Key result
Nicorandil use was associated with an increased risk of skin ulceration compared with nonusers (2.3% vs 0.4%; adjusted HR 1.85, 95% CI 1.27-2.69), especially in the first year of exposure.
Why the study?
Does oral nicorandil therapy increase the risk of skin ulceration in a general population?
Cohort (n=1,000,000)
Does oral nicorandil therapy increase the risk of skin ulceration in a general population?
Hazard Ratio: 1.85 (95% CI 1.27–2.69)
Absolute Event Rate: 2.3% vs 0.4%
Oral nicorandil therapy is associated with a significantly increased risk of skin ulceration, particularly in the first year of use, supporting regulatory warnings.
May warrant caution with nicorandil in ulcer-prone patients; leaves open need for causal confirmation in trials.
BACKGROUND: Although healthcare products regulatory agencies have issued warnings on risk of ulceration associated with the use of nicorandil, a population-based study has not been carried out. OBJECTIVES: To determine the relationship between use of nicorandil and skin ulceration. METHODS: We carried out a population-based study using a cohort of 1 million people assembled from Taiwan's national health insurance database. The association between nicorandil use and skin ulcers was estimated by a Cox proportional hazards regression model adjusting for a nicorandil-specific propensity score (PS) comprising of 86 potential predictors (c-statistic = 0·91). RESULTS: The prospective cohort was longitudinally followed from January 2005 to December 2009, during which 1268 new users of nicorandil and 771 136 nonusers were identified. A higher frequency of skin ulcers (29 of 1268; 2·3%) was observed for users of nicorandil compared with nonusers (3231 of 771 136; 0·4%). Compared with nonusers, the crude hazard ratio (HR) associating nicorandil use with skin ulcers was 5·52 [95% confidence interval (CI) 3·82-7·95] and the PS-adjusted HR was 1·85 (95% CI 1·27-2·69). A risk period analysis showed that the risk of skin ulceration among users of nicorandil was greatest in the first year. Subgroup analysis found that the interaction term reached statistical significance (P < 0·05) for age and diabetes. CONCLUSIONS: Use of nicorandil was found to be associated with an increased risk for skin ulceration, especially in the first year after incident exposure. We suggest that regulatory agencies re-evaluate the risk for skin ulceration associated with use of nicorandil.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2015) reported a cohort. Nicorandil vs. Nonusers was evaluated on Skin ulcers (HR 1.85, 95% CI 1.27-2.69). Nicorandil use was associated with an increased risk of skin ulceration compared with nonusers (2.3% vs 0.4%; adjusted HR 1.85, 95% CI 1.27-2.69), especially in the first year of exposure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: